Vitamin B7 Deficiency Exposes Hidden Metabolic Weakness in Cancer Cells
Cutting off biotin halts cancer cell growth by disabling a key enzyme, revealing a promising new therapeutic target.
Summary
Researchers at the University of Lausanne discovered that vitamin B7 (biotin) acts as a metabolic license for cancer cells, enabling them to survive when their primary fuel source, glutamine, runs low. Cancer cells are notoriously addicted to glutamine, but many escape treatments targeting this dependency by switching to alternative fuels like pyruvate. This switch requires a biotin-dependent enzyme called pyruvate carboxylase. Without biotin, the enzyme fails and cancer cells stop growing. The study also found that mutations in the FBXW7 gene, common in certain cancers, reduce pyruvate carboxylase levels, making those cancer cells even more dependent on glutamine and therefore more vulnerable to glutamine-blocking therapies. Published in Molecular Cell, the findings could help explain why some cancer treatments fail and point toward combination metabolic strategies.
Detailed Summary
Cancer cells are metabolic opportunists, and understanding how they fuel their growth is central to developing better treatments. A new study from the University of Lausanne, published in Molecular Cell, reveals that vitamin B7, commonly known as biotin, plays a surprising and critical role in enabling cancer cells to survive nutrient stress — and that removing it could shut down their escape route.
Many tumors are heavily dependent on glutamine, an amino acid essential for building proteins and DNA. Scientists have long viewed this glutamine addiction as a potential therapeutic target. However, cancer cells frequently outsmart glutamine-blocking therapies by switching to alternative carbon sources, particularly pyruvate. The new research shows this metabolic flexibility depends entirely on a mitochondrial enzyme called pyruvate carboxylase, which cannot function without biotin. Deprive cancer cells of biotin, and this escape route closes — cell growth halts.
The study also uncovered an important role for the FBXW7 gene, which is mutated in a significant subset of human cancers. When FBXW7 is mutated, pyruvate carboxylase levels drop, making cells less able to use pyruvate as a backup fuel. This forces those cancer cells into even deeper glutamine dependence, creating a sharper vulnerability that could be exploited therapeutically. Researchers confirmed that specific patient-derived FBXW7 mutations directly trigger this increased glutamine reliance.
These findings help explain a persistent clinical puzzle: why glutamine-targeting therapies often fail. Tumors with intact FBXW7 can simply reroute their metabolism. Tumors with FBXW7 mutations may be far more susceptible, suggesting that genetic profiling could guide treatment selection.
For now, this research is preclinical and does not suggest that biotin supplementation or restriction is a cancer therapy. The practical implication is for drug developers: targeting multiple metabolic pathways simultaneously, including the biotin-pyruvate carboxylase axis, may be necessary to effectively starve tumors of the flexibility they need to survive.
Key Findings
- Biotin (vitamin B7) enables cancer cells to use pyruvate as a backup fuel when glutamine is scarce, sustaining tumor growth.
- Removing biotin disables pyruvate carboxylase, blocking cancer cells' metabolic escape route and halting proliferation.
- FBXW7 gene mutations, common in certain cancers, reduce pyruvate carboxylase and increase glutamine dependency.
- Tumors with FBXW7 mutations may be significantly more vulnerable to glutamine-targeting therapies than others.
- Simultaneous targeting of multiple metabolic pathways may overcome cancer cells' notorious metabolic flexibility.
Methodology
This is a research summary based on a peer-reviewed study published in Molecular Cell, a high-impact journal, from the University of Lausanne. The findings are based on cellular and molecular biology experiments, including metabolomics and proteomics analyses, with validation using patient-derived gene mutations. Evidence quality is strong for preclinical research but has not yet been tested in human clinical trials.
Study Limitations
This is preclinical research conducted in cell models; human clinical validation is needed before any therapeutic conclusions can be drawn. The article does not specify which cancer types were studied, limiting generalizability. Readers should not interpret findings as a basis for modifying biotin supplementation without consulting a physician.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.